List of works - Hubing Shi

A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity.

scientific article published on 10 April 2018

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

scientific article

AIDE: annotation-assisted isoform discovery with high precision

scientific article published on 06 November 2019

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

scientific article

Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

scientific article published on 01 May 2019

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

scientific article published on 07 May 2019

HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity

scientific article published on 05 November 2018

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

scientific article published on 25 March 2019

Inhibition of programmed cell death protein ligand-1 (PD-L1) by benzyl ether derivatives: analyses of conformational change, molecular recognition and binding free energy

scientific article published on 24 January 2019

Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy

scientific article published on 10 November 2020

MDM4 is a key therapeutic target in cutaneous melanoma

scientific article published on 22 July 2012

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

scientific article

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

scientific article

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

scientific article

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

scientific article published on April 2012

The heparin binding motif of endostatin mediates its interaction with receptor nucleolin

scientific article

Therapy-induced tumour secretomes promote resistance and tumour progression

scientific article published on 25 March 2015

List of works by Hubing Shi

A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity.

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

AIDE: annotation-assisted isoform discovery with high precision

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

Inhibition of programmed cell death protein ligand-1 (PD-L1) by benzyl ether derivatives: analyses of conformational change, molecular recognition and binding free energy

Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy

MDM4 is a key therapeutic target in cutaneous melanoma

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

The heparin binding motif of endostatin mediates its interaction with receptor nucleolin

Therapy-induced tumour secretomes promote resistance and tumour progression